|
Prognostic significance of radiologic features of pneumonitis induced by anti-PD-1 therapy. |
|
|
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical |
Research Funding - Boehringer Ingelheim |
|
|
Speakers' Bureau - Boehringer Ingelheim; MSD |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bayer Yakuhin; Daiichi Sankyo; Nihon Medi-Physics |
|
|
Speakers' Bureau - Actelion; AstraZeneca; Chugai Pharma; Ono Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD Oncology |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
|
|
Speakers' Bureau - Actelion; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyorin; Lilly; MSD; Novartis; Torii Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Novartis; pfizer |
|
|
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly; Novartis; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical |
|
|
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical |